EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Red-Light Photodynamic Therapy with 10% ALA Gel for the Treatment of Keratoacanthoma: A Prospective Pilot Study

Jeffrey Cizenski, Karah Blair

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s827

DOI: 10.25251/wmg8c844 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Jeffrey Cizenski und 1 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Keratoacanthoma (KA) is a rapidly growing, well-differentiated squamous neoplasm that is generally considered a variant of squamous cell carcinoma (SCC). Although surgical excision remains the standard of care, nonsurgical treatment options may be desirable in selected patients. Red-light photodynamic therapy (PDT) with 10% aminolevulinic acid (ALA) gel is an established treatment for actinic keratoses and has demonstrated efficacy in superficial nonmelanoma skin cancers. This prospective pilot study evaluated red-light PDT with 10% ALA gel for the treatment of keratoacanthoma.

Methods

Five subjects with biopsy-confirmed KA or well-differentiated SCC measuring 0.5–1.5 cm on the trunk or extremities were enrolled. Lesions were debrided, treated with 10% ALA gel, and incubated under occlusion for 2.5 hours before red-light illumination. Subjects received two PDT treatments two weeks apart; one subject received a third treatment as clinically indicated. Clinical response was assessed 3 months after the final PDT treatment using a lesion score of 0–2, with 0 indicating no clinical evidence of remaining tumor. Tolerability during treatment was evaluated using a 10-point visual analog scale (VAS), and recurrence was assessed at the 3-month follow-up.

Results

All five subjects demonstrated complete clinical resolution at the 3-month follow-up, with lesion scores of 0, and no clinical recurrences were documented. Mean patient-reported pain scores were 3.3 during PDT #1 and 3.1 during PDT #2; the subject who underwent a third treatment reported a VAS score of 7.0. Lesion size progressively decreased across treatment visits, with complete clinical clearance maintained at 3 months.

Conclusion

In this prospective pilot study, red-light PDT with 10% ALA gel resulted in complete clinical resolution of KA in all five subjects, with no clinical recurrence observed at 3-month follow-up. Treatment was generally well tolerated during illumination. These preliminary findings suggest that red-light PDT with 10% ALA gel may represent a nonsurgical treatment option for selected keratoacanthomas. Larger prospective studies with longer follow-up are warranted to further characterize efficacy, recurrence rates, and durability of response. Support this Investigator-Initiated study was provided by Biofrontera Inc

Zitieren

APA

Cizenski, J., & Blair, K. (2026). Red-Light Photodynamic Therapy with 10% ALA Gel for the Treatment of Keratoacanthoma: A Prospective Pilot Study. SKIN The Journal of Cutaneous Medicine, 10(6), s827. https://doi.org/10.25251/wmg8c844

Vancouver

Cizenski J, Blair K. Red-Light Photodynamic Therapy with 10% ALA Gel for the Treatment of Keratoacanthoma: A Prospective Pilot Study. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s827. doi:10.25251/wmg8c844

BibTeX
@article{Cizenski2026,
  author = {Cizenski, Jeffrey and Blair, Karah},
  title = {Red-Light Photodynamic Therapy with 10% ALA Gel for the Treatment of Keratoacanthoma: A Prospective Pilot Study},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s827},
  doi = {10.25251/wmg8c844}
}
Kostenlos starten →